Wyeth Shifting R&D Funds To Early-Stage Compound Research And Licensing

Wyeth is moving R&D spend from Phase III projects to discovery and early stage programs in an effort to continue meeting its goal of submitting two NDAs for new molecular entities per year, R&D President Robert Ruffolo said